Vertex Pharmaceuticals Inc
featured
One biotech name has the best upside potential for 2013, pharmaceutical analyst Barbara Ryan says.
» Read MoreMore
-
NEW YORK, May 7- Only half of people in the United States who have ever been infected with hepatitis C get proper testing for the liver-destroying disease, U.S. health officials said on Tuesday.
-
May 1- Vertex Pharmaceuticals Inc:. *UBS raises target price to $86 from $60; rating buy. Reuters Station users, click. 1568.
-
One biotech name has the best upside potential for 2013, pharmaceutical analyst Barbara Ryan says.
-
Stocks reversed a two-day slump to close out the week on a positive note, with the S&P 500 rebounding after finishing below it 50-day moving average for the first time this year, but all three major averages still logged their worst weekly drop this year.
-
*Boston in virtual lockdown, trading volume could fall.
-
*IBM shares down, Google up after results. *McDonald's profit up, shares off as U.S. sales drop. NEW YORK, April 19- U.S. stocks were set to rise at the open on Friday, bouncing back a day after the S&P 500 index closed below its 50- day moving average for the first time this year.
-
U.S. stock index futures trimmed some gains Friday, with major averages poised to post their worst weekly declines this year, as investors reacted to the latest wave of earnings reports.
-
*IBM shares down, Google up after results. NEW YORK, April 19- U.S. stock index futures rose on Friday, setting the market up for a bounce back a day after the S&P 500 closed below its 50- day moving average for the first time this year.
-
Check out which companies are making headlines before the bell on Friday:
-
*Boston in virtual lockdown as police hunt down bomb suspect.
-
April 18- Vertex Pharmaceuticals Inc said its experimental drug improved lung function in adults with cystic fibrosis in a mid-stage trial, sending its shares 53 percent higher in after-hours trading.
-
April 18- Vertex Pharmaceuticals Inc said its experimental drug improved lung function in adults with cystic fibrosis in a mid-stage trial, sending its shares up sharply in after-hours trading.
-
Check out which companies are making headlines after the bell Thursday:
-
The "Fast Money" traders share their final trades of the day.
-
Cramer thinks any one of the following 3 stocks deserves a spot inside a properly diversified portfolio.
-
Spending on drugs to treat common diseases fell 1.5 percent among customers who receive prescription benefits through commercial insurers.
-
A rise in spending on specialty drug treatments offset that decline, however, and drove total U.S. payments for prescription drugs up 2.7 percent last year, Express Scripts Holding Co said on Tuesday. For Express Scripts, profit margins on generic drugs are higher than those on more-expensive branded drugs.
-
*Tested in genotype 2/ 3 patients who failed prior therapy. Feb 19- Gilead Sciences Inc said its experimental hepatitis C drug sofosbuvir, in a late-stage clinical study, was clearly superior to historical cure rates at both 12 and 16 weeks of treatment in patients who were not helped by prior therapy.
-
*Net loss of 35 cents per share in fourth quarter. *Sees 2013 revenue $1.1 bln to $1.25 bln. Jan 29- Vertex Pharmaceuticals Inc on Tuesday reported a third consecutive quarterly loss as sales of its hepatitis C drug, Incivek, again fell sharply while research and development spending rose.
-
*Net loss of 35 cents/ share in fourth quarter. *Sees 2013 revenue $1.1 bln to $1.25 bln. Jan 29- Vertex Pharmaceuticals Inc on Tuesday reported a third straight quarterly loss as sales of its hepatitis C drug, Incivek, again fell sharply while research and development spending rose.